Who is sponsoring NCT04177368?

NCT04177368 is sponsored by Assiut University.

What drugs are being tested in NCT04177368?

Interventions in NCT04177368: Theragran 60ml.

What condition does NCT04177368 study?

NCT04177368 studies Assessment of Nutrition in ESRD.

Is NCT04177368 still recruiting?

NCT04177368 is currently status unknown. Last updated 26 November 2019.

Last reviewed 2019-11-26 · How we verify

NCT04177368

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nutritional Assessment of Children With ESRD on Dialysis

Status unknown Last updated 26 November 2019

What this trial tests

trial testing Theragran 60ml in Assessment of Nutrition in ESRD in 55 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
1 July 2020

1 November 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	55
Start date	1 January 2020
Primary completion	1 July 2020
Estimated completion	1 November 2020

Drugs / interventions tested

Theragran 60ml

Conditions studied

Assessment of Nutrition in ESRD — all drugs for Assessment of Nutrition in ESRD →

Sponsor

Assiut University

Who can join

Adults 1 to 18, any sex, with Assessment of Nutrition in ESRD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Normal growth can be divided into four important phases: prenatal, infantile, childhood and pubertal. Nutrition is important at all phases of growth, but particularly so during the infantile phase because the rate of growth is higher than at any other time of life and is less dependent on growth hormone than during other phases. During the childhood phase, growth becomes more dependent on the GH/insulin-like growth factor-1 axis; growth rate decelerates continuously until the pubertal phase. The pubertal phase results from the coordination of GH and sex steroid production. Together they have an anabolic effect on muscle mass, bone mineralization and body proportions. It is another phase of rapid growth so that nutrition can again modify the genetic growth potential.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04177368 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 26 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04177368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing